Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) Return on Invested Capital (2019 - 2023)

Historic Return on Invested Capital for Denali Therapeutics (DNLI) over the last 5 years, with Q4 2023 value amounting to 0.18%.

  • Denali Therapeutics' Return on Invested Capital rose 1800.0% to 0.18% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.18%, marking a year-over-year increase of 1800.0%. This contributed to the annual value of 0.43% for FY2024, which is 2400.0% down from last year.
  • Per Denali Therapeutics' latest filing, its Return on Invested Capital stood at 0.18% for Q4 2023, which was up 1800.0% from 0.15% recorded in Q3 2023.
  • In the past 5 years, Denali Therapeutics' Return on Invested Capital registered a high of 0.06% during Q4 2020, and its lowest value of 0.51% during Q4 2019.
  • Over the past 5 years, Denali Therapeutics' median Return on Invested Capital value was 0.18% (recorded in 2023), while the average stood at 0.22%.
  • As far as peak fluctuations go, Denali Therapeutics' Return on Invested Capital soared by 5700bps in 2020, and later tumbled by -3900bps in 2022.
  • Quarter analysis of 5 years shows Denali Therapeutics' Return on Invested Capital stood at 0.51% in 2019, then skyrocketed by 112bps to 0.06% in 2020, then tumbled by -590bps to 0.3% in 2021, then decreased by -22bps to 0.37% in 2022, then skyrocketed by 50bps to 0.18% in 2023.
  • Its Return on Invested Capital stands at 0.18% for Q4 2023, versus 0.15% for Q3 2023 and 0.15% for Q2 2023.